CSL Behring Appoints Helena Bragd as New General Manager for the Nordic Region

Helena Bragd is the new General Manager of CSL Behring Nordic Region – Sweden, Denmark, Norway, Finland, and Iceland. She succeeds former General Manager Aymeric Angé who has moved on to an international role as Senior Director Tender and Tolling Strategy and Operations within the company.

”I am happy and proud to take on the role as General Manager Nordics for CSL Behring – a values-driven company focused on innovation and helping patients with rare and serious diseases. I am passionate about strengthening Nordic healthcare with a particular focus on improved patient care”, says Helena Bragd.

Helena Bragd holds a master’s degree in international business administration from Lund University and ESCP Business School and has a solid professional background in Life Sciences.

She most recently worked at BD (Becton Dickinson), where she served as Nordic General Manager for 8 years. Before that, she held key strategic positions at Eli Lilly, Johnson & Johnson and ResMed. Between 2019 and 2023, she was also chairman of the board of directors for the industry association Swedish MedTech.

”I look forward to exploring CSL Behring’s therapeutic areas and products and getting to know all colleagues in the Nordics. Together, we will work dedicatedly to reach more healthcare professionals and strengthen our relationships with patient organizations, as well as regulatory agencies”, says Helena Bragd.

Gene Therapy for Haemophilia B in the Nordics

Currently CSL Behring is introducing the first EMA approved gene therapy for haemophilia B in the Nordics. In October 2024, CSL Behring announced an innovative reimbursement agreement in Denmark, and recently the first Danish patients with haemophilia B were treated with the company’s gene therapy.

Several other new innovative medicines are in various stages of development or in the EMA approval process.

Driven by Our Promise to Save Lives

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We develop and deliver innovative medicines for treating bleeding disorders, immune deficiencies, and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha 1 Antitrypsin Deficiency, among others.

We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.

Our parent company, CSL, headquartered in Melbourne, Australia, employs more than 32,000 people, and delivers its lifesaving therapies to people in more than 100 countries.

Visit our local CSL Behring websites: Sweden, Denmark, Norway, Finland.